Regenxbio
Clinical-stage biotech company developing AAV gene therapies for rare and retinal diseases.
Check the tech stack behind regenxbio.com. Find a founder email at regenxbio.com.
About
REGENXBIO is a clinical-stage biotechnology company focused on developing gene therapies using its proprietary NAV Technology Platform, which utilizes adeno-associated virus (AAV) vectors. The company aims to improve lives by delivering one-time treatments for rare and retinal diseases, as well as metabolic and neurodegenerative conditions. Their pipeline includes investigational therapies for Duchenne muscular dystrophy, MPS II, MPS I, and wet age-related macular degeneration. Teams look it up for Biotech, MedTech, HealthTech.
Frequently asked
What does Regenxbio do?
Regenxbio is a Biotech company that offers Software. Teams look it up for MedTech, HealthTech, Drug Discovery. It is based in Rockville, United States and was founded in 2008. Public records show about 396 people and $180M raised. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has Regenxbio raised?
Regenxbio has raised a total of $180M in funding. The most recent round on record is Funding Round.
Where is Regenxbio headquartered?
Regenxbio is headquartered in Rockville, United States.
When was Regenxbio founded?
Regenxbio was founded in 2008.
What industry does Regenxbio operate in?
Regenxbio operates in Biotech, MedTech, HealthTech, Drug Discovery, Clinical Trials.
How many employees does Regenxbio have?
Regenxbio has approximately 396 people on record.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.